APRE · Aprea Therapeutics, Inc.
Market Cap
$10.07M
Shares
12.59M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.84
Open$0.78
Day$0.78–0.90
52W close$0.59–1.65
Avg vol 30d376K
Short int5K · 0.0% float · 1.0d
Short vol35%
Last earningsMay 16, 2022
DataFeb 2023–Sep 2026
Filing10-Q · Aug 12
Raw chart and full-history price indicators begin at the captured split on Feb 13, 2023; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+1%
above
Price vs 50-day avg
+17%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
23%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+40%
trailing
6-month return
+6%
trailing
YTD return
−2%
this year
Relative strength
−6%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+27% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.04% of float · ▼ -86.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — mid 3-yr range
Squeeze score
33
low risk · 0–100
Fundamentals
EPS growth
+18%
Y/Y
Free cash flow
$-12.9M
Quant / Vol
risk profile
Volatility
93%
annualized · 1-yr
Max drawdown
−64%
past year
ATR
11.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+1%
Bullish
Price vs 50-day avg
+17%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
23%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+27% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.04% of float · ▼ -86.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 23%
Range high $2
vs 200-day avg +1%
vs 50-day avg +17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
APRE
this stock
Aprea Therapeutics, Inc.
|
$10.07M | -2.0% | — | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.8% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +6.7% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.3% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.51B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Feb 13, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| APRE | -12.0% | +39.5% | +6.2% | +4.5% | -2.0% |
| SPY | -0.5% | -1.2% | +12.6% | -0.7% | +11.7% |
| vs SPY | -11.5% | +40.8% | -6.4% | +5.2% | -13.7% |
Key facts
CIK
1781983
CUSIP
03836J201
13F (30d)
28 filings
28 filers
Visit website
Investor relations